Patent Term Application for ORLYNVAH (sulopenem etzadroxil and probenecid), Patent No. 7,795,243 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0161

Patent Term Application for ORLYNVAH (sulopenem etzadroxil and probenecid), Patent No. 7,795,243

Documents

Comments

Description

OPEN

Comment Period OpensJan 15, 2025

Comment Period ClosesApr 28, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH FR Doc: 2026-03848	Feb 26, 2026	--

CDER

Patent Term Application

Cooley LLP

Pfizer, Inc

ORLYNVAH (sulopenem etzadroxil and probenecid)

Patent No. 7,795,243

OPEN